Edgewise Therapeutics Advances HFpEF Treatment with Phase 2 Trial Initiation
Event summary
- Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, an oral selective cardiac sarcomere modulator targeting HFpEF.
- The trial will enroll approximately 90 adults with symptomatic HFpEF and LVEF of at least 50%, testing 25 mg or 50 mg doses of EDG-15400 against placebo.
- Edgewise will present trial design and Phase 1 data at the HFSA Annual Scientific Meeting 2026 on October 10 and 12.
- EDG-15400 aims to address impaired cardiac relaxation, a key feature of HFpEF not adequately treated by current therapies.
The big picture
Edgewise Therapeutics is targeting a critical gap in heart failure treatment with its Phase 2 trial for EDG-15400, a drug designed to address diastolic dysfunction in HFpEF patients. This trial represents a strategic push into an underserved cardiometabolic market, where current therapies often fail to address the root cause of symptoms. The company's focus on selective cardiac sarcomere modulation could differentiate EDG-15400 if preclinical improvements in diastolic function translate into clinical benefits.
What we're watching
- Clinical Efficacy
- Whether EDG-15400 can demonstrate meaningful improvements in diastolic function and symptom relief in HFpEF patients.
- Regulatory Pathway
- The pace at which Edgewise can advance EDG-15400 through Phase 2 and into potential Phase 3 trials based on interim data.
- Market Opportunity
- How Edgewise positions EDG-15400 in the competitive landscape of HFpEF treatments, given the unmet needs in this patient population.